X0306 4 2018-03-02 0 0000792977 AMAG PHARMACEUTICALS INC. AMAG 0001214939 HEIDEN WILLIAM K C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451 1 1 0 0 President & CEO Common Stock 2018-03-02 4 A 0 45500 A 318061 D Common Stock 2018-03-02 4 A 0 45500 A 363561 D Common Stock 2018-03-02 4 F 0 10546 21.00 D 353015 D Stock Option (Right to Buy) 21.00 2018-03-02 4 A 0 100000 A 2028-03-02 Common Stock 100000 100000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on March 2, 2019. Not applicable. These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending March 1, 2021 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 9,999 RSUs on February 23, 2018, 10,002 RSUs on February 26, 2018, 3,900 RSUs on February 27, 2018, and 11,999 RSUs on March 1, 2018. Due to the black-out policies implemented by the Issuer, the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until March 2, 2018, at which time an aggregate of 10,546 shares were withheld to satisfy the reporting person's applicable tax obligations. Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. /s/ Nancy R. Smith, attorney-in-fact 2018-03-06